Physiomics (GB:PYC) has released an update.
Physiomics plc, a leader in mathematical modelling and biostatistics, has released its end-of-year results presentation on its website, showcasing its role in supporting drug development and personalized medicine. The company continues to leverage its cutting-edge Virtual Tumour technology, having influenced over 100 commercial projects with major clients like Merck KGaA and CRUK. Investors can access the latest insights into the company’s strategic direction and market position via the updated presentation.
For further insights into GB:PYC stock, check out TipRanks’ Stock Analysis page.
